ROMANO KATHRYN
SEC CIK 1801385 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | CAO | 22.4K | — | $12.67M | 23 | 2022-02-26 | 2026-03-02 |
Most active insiders at KRYS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Krishnan Suma | Pres, R, D, Dir, 10% | — | $34.27M |
| 2 | Krishnan Krish S | Pres, CEO, Dir, 10% | — | $34.27M |
| 3 | JANNEY DANIEL | Dir | — | $19.40M |
| 4 | ROSSI DINO A | Dir | — | $13.18M |
| 5 | ROMANO KATHRYN | CAO | — | $3.60M |
| 6 | Thomas John Charles | EVP, GC | — | $541.2K |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2026-02-27 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | F - Tax | $275.64 | -3,502 | 23.1K | -13% | -$965.3K |
| DM | 2026-03-03 | 2026-02-27 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | M - OptEx | $0.00 | +8,050 | 23.4K | +53% | $0 |
| D | 2026-03-03 | 2026-03-02 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | S - Sale+OE | $267.60 | -750 | 22.4K | -3% | -$200.7K |
| DM | 2026-02-11 | 2026-02-09 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | S - Sale+OE | $272.14 | -12.5K | 29.8K | -30% | -$3.40M |
| D | 2026-02-11 | 2026-02-09 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | G - Gift | $0.00 | -750 | 18.6K | -4% | $0 |
| D | 2026-02-11 | 2026-02-09 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | M - OptEx | $63.55 | +12.5K | 31.8K | +65% | +$794.4K |
| DM | 2025-02-28 | 2025-02-28 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | M - OptEx | $0.00 | +12.5K | 22.8K | +121% | $0 |
| DM | 2025-02-28 | 2025-02-26+ | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | F - Tax | $178.44 | -8,054 | 15.3K | -35% | -$1.44M |
| D | 2025-02-28 | 2025-02-27 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | S - Sale+OE | $175.22 | -750 | 12.6K | -6% | -$131.4K |
| DM | 2024-03-01 | 2024-02-28 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | M - OptEx | $63.55 | +7,500 | 13.1K | +135% | +$476.6K |
| DM | 2024-03-01 | 2024-02-28 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | S - Sale+OE | $166.05 | -7,500 | 12.9K | -37% | -$1.25M |
| DM | 2024-03-01 | 2024-02-28 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | M - OptEx | $31.77 | +10.0K | 17.9K | +126% | +$317.8K |
| D | 2024-03-01 | 2024-02-28 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | F - Tax | $163.08 | -2,314 | 15.6K | -13% | -$377.4K |
| DM | 2024-03-01 | 2024-02-28 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | S - Sale+OE | $165.88 | -5,000 | 12.9K | -28% | -$829.4K |
| D | 2024-02-28 | 2024-02-26 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | F - Tax | $157.00 | -1,533 | 11.0K | -12% | -$240.7K |
| DM | 2024-02-28 | 2024-02-26 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | S - Sale+OE | $136.91 | -8,087 | 12.6K | -39% | -$1.11M |
| DM | 2024-02-28 | 2024-02-26+ | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | CAO | M - OptEx | $52.26 | +10.0K | 12.9K | +341% | +$522.6K |
| D | 2024-01-24 | 2024-01-22 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | CAO | M - OptEx | $52.26 | +2,500 | 15.1K | +20% | +$130.7K |
| D | 2024-01-24 | 2024-01-22 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | CAO | S - Sale+OE | $130.00 | -2,500 | 12.6K | -17% | -$325.0K |
| DM | 2023-05-23 | 2023-05-19+ | KRYS | Krystal Biotech, Inc. | Romano Kathryn | CAO | M - OptEx | $55.08 | +50.0K | 15.5K | New | +$2.75M |
| DM | 2023-05-23 | 2023-05-19+ | KRYS | Krystal Biotech, Inc. | Romano Kathryn | CAO | S - Sale+OE | $101.60 | -53.4K | 12.6K | -81% | -$5.43M |
| D | 2023-02-28 | 2023-02-26 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | CAO | F - Tax | $78.46 | -2,144 | 16.0K | -12% | -$168.2K |
| D | 2022-03-01 | 2022-02-26 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | CAO | F - Tax | $62.50 | -1,472 | 18.1K | -8% | -$92.0K |
Purchase Sale Sale after option exercise All abbreviations